These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9471790

  • 1. [Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
    Ptuskin VV, Uss AL, Demina EA, Chervonobab IuV, Milanovich NF, Tupitsyn NN, Larionova VB, Batan ZE, Kondrat'eva NE, Zmachinskiĭ VA, Andreeva LA, Snegir' VM, Mkheidze DM, Chimishkian KL.
    Ter Arkh; 1997; 69(10):49-55. PubMed ID: 9471790
    [Abstract] [Full Text] [Related]

  • 2. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 4. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
    Lumley MA, Milligan DW, Knechtli CJ, Long SG, Billingham LJ, McDonald DF.
    Bone Marrow Transplant; 1996 Mar; 17(3):383-8. PubMed ID: 8704691
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 6. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM.
    J Clin Oncol; 2003 Nov 15; 21(22):4151-6. PubMed ID: 14615443
    [Abstract] [Full Text] [Related]

  • 7. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 15; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 8. [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
    Uss AL, Zmachinskiĭ VA, Milanovich NF, Skriagin AE, Dziuba EV, Vlasenkova SV, Solov'eva NS, Batan ZE, Mitskevich PB, Zavgorodniaia IL, Aleĭnikova OV, Zhavrid EA.
    Vopr Onkol; 2000 Aug 15; 46(5):619-23. PubMed ID: 11202200
    [Abstract] [Full Text] [Related]

  • 9. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP, Stiff PJ, Toor AA, Parthasarathy M.
    Biol Blood Marrow Transplant; 2003 Mar 15; 9(3):177-82. PubMed ID: 12652468
    [Abstract] [Full Text] [Related]

  • 10. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L, Ladeb S, Lakhal A, Ben Othman T, Abdelkefi A, Ben Abdeladhim A.
    Tunis Med; 2007 Jan 15; 85(1):35-8. PubMed ID: 17424707
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
    Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A, German Hodgkin's Lymphoma Study Group (GHSG).
    Ann Hematol; 2002 Aug 15; 81(8):424-9. PubMed ID: 12223998
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 13. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
    Bone Marrow Transplant; 2008 Apr 15; 41(7):613-9. PubMed ID: 18071290
    [Abstract] [Full Text] [Related]

  • 14. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain.
    Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernández JM, Muñoz A, Olivé T, Fernández-Delgado R, Cubells J, Diaz MA, Sastre A.
    Bone Marrow Transplant; 2000 Jan 15; 25(1):31-4. PubMed ID: 10654011
    [Abstract] [Full Text] [Related]

  • 15. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.
    Bone Marrow Transplant; 2004 Oct 15; 34(7):581-7. PubMed ID: 15273714
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
    Oncol Rep; 2005 Oct 15; 14(4):933-40. PubMed ID: 16142354
    [Abstract] [Full Text] [Related]

  • 17. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM.
    Bone Marrow Transplant; 2001 Feb 15; 27(4):387-96. PubMed ID: 11313668
    [Abstract] [Full Text] [Related]

  • 18. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A.
    Cancer; 2003 Jun 01; 97(11):2748-59. PubMed ID: 12767087
    [Abstract] [Full Text] [Related]

  • 19. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb 01; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B.
    Ann Hematol; 2005 Jul 01; 84(7):462-73. PubMed ID: 15726362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.